Notes on the Design of Bioequivalence Study
Lopinavir/Ritonavir

Notes on the design of bioequivalence studies with products invited for submission to the WHO Prequalification Unit – Medicines Assessment Team (PQT/MED) are issued to aid manufacturers with the development of their product dossier. Deviations from the approach suggested below can be considered acceptable if justified by sound scientific evidence.


Below, additional specific guidance is provided on the invited immediate release products containing lopinavir and ritonavir.

**Pharmacokinetics of lopinavir/ritonavir**

Ritonavir inhibits the metabolism of lopinavir, thereby increasing the plasma levels of lopinavir.

Multiple dosing with 400/100 mg of lopinavir / ritonavir twice daily for two weeks and without meal restriction produced $C_{\text{max}}$ occurring approximately 4 hours after administration. After a single dose, $T_{\text{max}}$ was observed between 3 and 4 hours.

Administration of a single 400/100 mg dose of lopinavir / ritonavir tablets under fed conditions (high fat, 872 kcal, 56% from fat) compared to fasted state was associated with no significant changes in $C_{\text{max}}$ and AUC_{inf}. Therefore, lopinavir/ritonavir tablets may be taken with or without food. However, the oral solution should be taken with food since administration of the oral solution with a moderate fat meal (500–682 Kcal, 23 to 25% calories from fat) increased lopinavir AUC and $C_{\text{max}}$ by 80 and 54%, respectively, and administration of the oral solution with a high fat meal (872 Kcal, 56% from fat) increased lopinavir AUC and $C_{\text{max}}$ by 130% and 56%, respectively.

The effective (peak to trough) half-life of lopinavir over a 12-hour dosing interval averaged 5–6 hours. After a single dose administration, the elimination half-life was of 4–6 hours approximately.

**Pharmacokinetics of ritonavir**

After oral administration, ritonavir peak plasma concentrations are observed after approximately 3–4 hours.

Ritonavir is metabolized by the hepatic cytochrome P450 system, primarily by the CYP3A isozyme family and to a lesser extent by the CYP2D6 isofrom. Low doses of ritonavir have shown profound effects on the pharmacokinetics of other protease inhibitors (and other products metabolized by CYP3A4) and other protease inhibitors may influence the pharmacokinetics of ritonavir. Ritonavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC. Ritonavir elimination half-life when administered with lopinavir has been reported to be 5–6 hours.

**Guidance for the design of bioequivalence studies**

Taking into account the pharmacokinetic properties of lopinavir and ritonavir, the following guidance with regard to the study design should be taken into account:

**Design**: A single-dose cross-over design is recommended.
**Dose:** As the EoI includes 200/50 mg and 100/25 mg tablets and 40/10 mg granules/minitablets/pellets, the highest strength 200/50 mg strength is recommended for the bioequivalence study, provided the conditions are fulfilled to waive the additional 100/25 mg strength.

**Fasted/fed:** The bioequivalence study should be conducted in the fasted state if the tablets are used as reference, however, the study should be conducted in the fed state if the oral solution is used as reference.

If the dosing instructions for a proposed 40/10 mg granules/minitablets/pellet product indicate that it is to be taken sprinkled on food, the bioequivalence study should follow these dosing instructions. Therefore, the test product granules/minitablets/pellets should be sprinkled on a paediatric-age appropriate meal (e.g. apple sauce) and the reference product (e.g. oral solution or tablet) should be taken 30 minutes after starting the intake of the same type of meal.

If the dosing instructions of the 40/10 mg granules/minitablets/pellets indicate that they should be dispersed in a small amount of water, the bioequivalence study should follow these dosing instructions. Therefore, the test product granules/minitablets/pellets should be dispersed in a small amount of water (e.g. 20–40 mL) and the reference product (i.e. tablet) should be taken in the fasted state with a glass of water (e.g. 240 mL).

**Subjects:** Healthy volunteers should be recruited. It is not necessary to include patients in the bioequivalence study.

**Parent or metabolite data for assessment of bioequivalence:** The parent drug is considered to best reflect the biopharmaceutical quality of the product. The data for the parent compound should be used to assess bioequivalence of lopinavir / ritonavir.

**Sample size:** Lopinavir and ritonavir pharmacokinetic parameters, C<sub>max</sub> and AUC<sub>0-t</sub>, in the fasting state seem to possess moderate intra-subject variability (25–30%), although high variability (>30%) has been observed in some study. These data may facilitate the calculation of a sufficient sample size for the cross-over bioequivalence study.

**Washout:** Taking into account the elimination half-life of lopinavir and ritonavir in the fasted state of up to 6 h, a washout period of 7 days is considered sufficient to prevent carry-over.

**Blood sampling:** The blood sampling should be intensive in the first 5 hours. It is not necessary to take samples after 24 hours. For example, blood samples might be taken at pre-dose, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 9.00, 10.00, 12.00, 16.00, and 24.00 h after drug administration.

**Analytical considerations:** Information currently available to PQT/MED indicates that it is possible to measure lopinavir and ritonavir in human plasma using LC-MS/MS analytical methodology. The bioanalytical method should be sufficiently sensitive to detect concentrations that are 5% of the C<sub>max</sub> in most profiles of each formulation (test or comparator). The bioanalytical method of lopinavir should be validated in the presence of ritonavir and vice versa.

**Statistical considerations:** The data for lopinavir and ritonavir should meet the following bioequivalence standards in a single-dose cross-over design study:

- The 90% confidence interval of the relative mean AUC<sub>0-t</sub> of the test to reference product should be within 80.00–125.00%.
- The 90% confidence interval of the relative mean C<sub>max</sub> of the test to reference product should be within 80.00–125.00%.